Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

In this MEDtalk, associate professor Timothy F. Burns presents targetable treatment options for patients with early-stage non-small cell lung cancer (NSCLC), explicitly targeting the epidermal growth factor receptor (EGFR).